Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3)
Also known as: IGFBP-3
Use
The Insulin-Like Growth Factor Binding Protein-3 (IGFBP-3) test is not recommended as a first-line investigation for growth disorders but is useful in the evaluation of suspected anterior hypopituitarism. It can assist in understanding various growth-related conditions in conjunction with other clinical assessments.
Special Instructions
This test is approved for use in New York state. Ensure proper specimen collection to avoid sample rejection; serum separator tubes or green sodium heparin tubes are acceptable. It is crucial to separate serum from cells promptly and store samples appropriately to maintain stability.
Limitations
Test results may be influenced by the presence of hemolyzed or lipemic samples, which are not acceptable. The test is performed using quantitative chemiluminescent immunoassay, which may have inherent limitations regarding specificity and sensitivity when detecting protein variations or abnormalities. Additionally, due to physiological variations, reference intervals may vary significantly according to age and Tanner stage.
New York Approved
Methodology
Immunoassay (CLIA)
Biomarkers
LOINC Codes
- 2483-6
Result Turnaround Time
1-2 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
0.5 mL
Minimum Volume
0.3 mL
Container
ARUP Standard Transport Tube
Collection Instructions
Collect using a serum separator tube or green (sodium heparin) tube.
Storage Instructions
Store and transport the sample frozen to preserve its stability.
Causes for Rejection
Tissue or urine. Grossly hemolyzed or lipemic specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 1 week |
| Frozen | 1 year |